COVID-19 Update with Ola Landgren - HealthTree for Multiple Myeloma
[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account

COVID-19 Update with Ola Landgren, MD, PhD, MSKCC

COVID-19 Update with Ola Landgren, MD, PhD, MSKCC image

COVID-19 Update with Ola Landgren, MD, PhD, MSKCC

Podcast
event Apr 13, 2020 / 11:00AM MDT
link icon facebook logo X logo linkedin logo reddit logo email icon

Event Description

C. Ola Landgren, MD, PhD
Memorial Sloan Kettering Cancer Center 
Interview Date: April 13, 2020

Myeloma patients want to know how to manage their care, visits and tests during the COVID-19 crisis. Dr. Landgren has been treating myeloma patients in the midst of this intense situation and shares how he is caring for his myeloma patients at this time. He notes an incredible effort that includes telemedicine, social distancing and protecting the patient at every touch (or non-touch point). Treatments are remaining steady, although things like stem cell transplant are being delayed. Progress is continuing on upcoming approvals by the FDA, which is heartening news for myeloma patients. Learn more in this key update with Dr. Landgren. 

Thanks to our episode sponsor

Schedule & Agenda

Event panelist Dr. Ola Landgren & Jenny Alhstrom
11:00 AM
Discussion
Dr. Ola Landgren & Jenny Alhstrom

Speakers & Moderators

The panelist C. Ola Landgren, MD, PhD
C. Ola Landgren, MD, PhD

C. Ola Landgren, MD, PhD, is Professor of Medicine, Chief of the Myeloma Program, and Leader of the Experimental Program at the University of Miami Sylvester Cancer Center. Read more about his move to Miami here. Dr. Landgren is a pioneer in the drug development and minimal residual disease (MRD) testing in myeloma. In collaboration with colleagues throughout the world, he develops new strategies (including cell-based, molecular-based, and imaging-based) and continues to be a leader of using advanced MRD testing in clinical trials. He is involved in the service’s rational treatment program (small molecule, monoclonal antibody, immune-based) for newly diagnosed, relapsed and refractory myeloma and amyloidosis patients. His research focuses on early drug development, advanced disease monitoring by new minimal residual disease (MRD) assays and biomarkers, and immune-PET to monitor treatment. He also studies mechanism and markers of progression from MGUS/smoldering myeloma to symptomatic multiple myeloma, and the identification of high-risk precursor patients who may be candidates for early treatment. Prior to joining Miami, Dr. Landgren was the Chief Attending Physician of the Myeloma Service at Memorial Sloan Kettering and Professor of Medicine at the Weill Cornell Medical College in New York City and Chief of the Multiple Myeloma Section of the National Cancer Institute in Bethesda, MD. Dr. Landgren received his MD at Karolinska Institute in Stockholm, Sweden; and he has had fellowships at Karolinska University Hospital and the National Cancer Institute. He is a frequent speaker at national and international meetings, and has published more than 400 peer-reviewed papers.

Read Bio
The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

Thanks to our sponsors:
Johnson and Johnson logo
Sanofi logo
Pfizer logo
GSK logo
Regeneron logo
All HealthTree resources available anywhere, anytime
Download our App
Download iOS App Download Android App
iphone app mockup
newsletter icon

Get the Latest Hepatosplenic T-Cell Lymphoma Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.